Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEGEND: LR-GEM vs R-GEM-P in DLBCL
NCT02060656Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Sep 2013
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Complete Response Rate at 12 weeks. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02060656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02060656.